Corvus Stock Spikes On Heels Of Strong Eczema Study Results

Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) on Tuesday shared data from cohort 4 of the Phase 1 trial evaluating soquelitinib in patients with moderate-to-severe atopic dermatitis.

In reaction to the positive data, Corvus Pharmaceuticals’ stock is trading higher with a session volume of 30.79 million compared to the average volume of 1.33 million.

The cohort 4 data demonstrated favorable safety and efficacy results consistent with those from cohorts 1-3, including a deeper response in cohort 4 over the 8-week treatment period compared to the 4-week treatment period.

The results also showed clinical activity in patients who had received prior systemic therapies.

The mean baseline EASI (Eczema Area and Severity Index) score in cohort 4 was 25.7 for the patients treated with soquelitinib and 21.9 for patients who received placebo.

Across all four cohorts (n=72), 35% of patients had received prior systemic therapies (n=25), including 50% of patients (n=12) in cohort 4. Overall, all four cohorts showed meaningful responses in the soquelitinib treatment groups compared to placebo for clinically significant endpoints of EASI 75 and IGA (Investigator Global Assessment) 0 or 1.

At day 56, the mean percent reduction in EASI for patients receiving soquelitinib in cohort 4 (n=12) was 72%, compared to 40% for patients receiving placebo (n=10).

The kinetics of response demonstrated continuous improvement from day 28 to day 56, with widening separation of the response curve compared to the placebo.

Two placebo patients experienced disease flares requiring therapy during the 56-day treatment period compared to none in the soquelitinib group.

Biomarker Data

Reduction in serum IL-4 cytokine was observed in cohorts 3 and 4, both during the treatment period and in the post-treatment period, including a dose-dependent response, with cohort 4 patients showing the largest reductions in IL-4 out to day 86.

Biomarker data from cohorts 1 through 3 show a reduction in serum IL-5 cytokine for cohorts 1 through 3 compared to placebo, including a dose-dependent response, with cohort 3 patients showing the largest reductions in IL-5 compared to placebo. 

The reduction in serum IL-5 occurred as early as day 8 of therapy. Serum IL-17 and TARC levels were also lower.

As of January 15, no new safety signals have been observed. Reported adverse events occurred in 41.7% of soquelitinib patients and 50% of placebo patients; all were Grade 1-2 and did not result in any dose modifications or interruptions.

No severe or serious adverse events were reported. No significant lab abnormalities were seen.

Upcoming Phase 2 Eczema Trial

Corvus is on track to initiate a Phase 2 clinical trial of soquelitinib for atopic dermatitis in the first quarter of 2026.

The eczema trial is anticipated to enroll approximately 200 patients with moderate-to-severe atopic dermatitis who have failed at least one prior topical or systemic therapy.

The trial is anticipated to enroll four cohorts of 50 patients each, with soquelitinib doses of 200 mg once per day, 200 mg twice per day, and 400 mg once per day, along with a placebo group.

Price Action: CRVS stock is up 140% at $19.28 at the last check on Tuesday.

Image: Shutterstock